CC BY 4.0 · Glob Med Genet 2021; 08(03): 095-099
DOI: 10.1055/s-0041-1725157
Original Article

Evaluation of Serum Immunoglobulins (IgG, IgA, IgM) and Circulating Immune Complexes in Oral Precancer and Cancer Patients

Pooja Madki
1   Department of Oral Medicine and Radiology, SB Patil Dental College and Hospital, Karnataka, India
,
Mandya Lakshman Avinash Tejasvi
2   Department of Oral Medicine and Radiology, Kamineni Institute of Dental Sciences, Narketpally, Telangana, India
,
Geetha Paramkusam
3   Private Practice, Sri Venkateswara Dental Clinic, Hyderabad, Telangana, India
,
Ruheena Khan
4   Private Practice, Hyderabad, Telangana, India
,
Shilpa J.
4   Private Practice, Hyderabad, Telangana, India
› Author Affiliations
Funding None.

Abstract

Objectives The aim of the present study is to evaluate the role of immunoglobulins (IgA, IgG, and IgM) and circulating immune complexes (CIC) as tumor marker in oral cancer and precancer patients.

Materials and Methods The present study was performed on 45 individuals subdivided into three groups, that is, oral precancer, oral cancer and healthy individuals, and levels of immunoglobulins, and CIC was estimated by turbidometry and ELISA method.

Results In the present study, the mean serum IgA levels in oral precancer were 161.00 ( ±  118.02) mg/dL, oral cancers were 270.67 ( ±  171.44) mg/dL, and controls were 133.73 ( ±  101.31) mg/dL. Mean serum levels of IgG in oral precancer were 1,430.87 ( ±  316) mg/dL, oral cancers were 1,234.27 ( ±  365.42) mg/dL, and controls were 593.87 ( ±  323.06) mg/dL.

Conclusion We found that the levels of serum IgG and IgA were elevated consistently in precancer and cancer group, and Serum IgM levels were increased only in precancer. Also, significant increase in serum CIC levels were seen in oral precancer and cancer group on comparison with control.



Publication History

Article published online:
31 March 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Jane C, Nerurkar AV, Karjodkar FR. Circulating immune complexes (CIC) as marker for disease progress in oral cancer. Indian J ClinBiochem 2007; 22 (02) 114-117
  • 2 Khanna SS, Karjodkar FR. Circulating immune complexes and trace elements (Copper, Iron and Selenium) as markers in oral precancer and cancer: a randomised, controlled clinical trial. Head Face Med 2006; 2 (33) 33
  • 3 Urban D, Catane R. Serum tumor markers in oncology. Isr Med Assoc J 2009; 11 (02) 103-104
  • 4 Hurley WL, Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients 2011; 3 (04) 442-474
  • 5 Parveen S, Taneja N, Bathi RJ, Deka AC. Evaluation of circulating immune complexes and serum immunoglobulins in oral cancer patients--a follow up study. Indian J Dent Res 2010; 21 (01) 10-15
  • 6 Manikantan NS, Balakrishnan D, Kumar ADM, Shetty B. Tumor markers: at a glance. Oral MaxillofacPathol J 2014; 5 (01) 437-440
  • 7 Greenberg MS, Glick M, Ship JA. Immunologic diseases. In: Burket's Oral Medicine. 11th ed.. Hamilton: BC Decker Inc.; 2008: 435-460
  • 8 Ananthnarayan R, Paniker CK. Textbook of Microbiology. 6th ed.. Chennai: Orient Longman Publisher; 2000: 82-84
  • 9 Divya VC, Sathasivasubramanian S. Estimation of serum and salivary immunoglobulin G and immunoglobulin A in oral pre-cancer: a study in oral submucous fibrosis and oral lichen planus. J Nat SciBiol Med 2014; 5 (01) 90-94
  • 10 Patidar KA, Parwani RN, Wanjari SP. Correlation of salivary and serum IgG, IgA levels with total protein in oral submucous fibrosis. J Oral Sci 2011; 53 (01) 97-102
  • 11 Sklavounou AD, Laskaris G, Angelopoulos AP. Serum immunoglobulins and complement (C'3) in oral lichen planus. Oral Surg Oral Med Oral Pathol 1983; 55 (01) 47-51
  • 12 Mahdi MA. Immunoglobulins levels in sera of patients with neoplasia. MagallatDiyalá Li-l-'ulum al-Zira'iyyat 2011; 3 (01) 54-59
  • 13 Dawood RM, Hasan HR. Assessment of salivary and serum proteins in patients with oral tumors. Baghdad Science Journal 2013; 10 (03) 934-944
  • 14 Taneja L, Bagewadi A, Keluskar V, Arya V. Estimation of major immunoglobulin levels in patients with oral submucous fibrosis. J Cranio Max Dis 2015; 4: 16-20
  • 15 Mackey IR, Burket FM. Autoimmune diseases. Springfield, IL: Charles C Thomas Publisher; 1963: 16-17
  • 16 Yamanaka N, Himi T, Harabuchi Y, Hoki K, Kataura A. Soluble immune complexes and squamous cell carcinoma-related antigens in patients with head and neck cancer. Cancer 1988; 62 (09) 1932-1938
  • 17 Stanilova SA, Slavov ES. Comparative study of circulating immune complexes quantity detection by three assays--CIF-ELISA, C1q-ELISA and anti-C3 ELISA. J Immunol Methods 2001; 253 (1–2): 13-21
  • 18 Höffken K, Price MR, McLaughlin PJ, Moore VE, Baldwin RW. Circulating immune complexes in rats bearing chemically induced tumors. I. Sequential determination during the growth of tumours at various body sites. Int J Cancer 1978; 21 (04) 496-504
  • 19 Papsidero LD, Nemoto T, Snyderman MC, Chu TM. Immune complexes in breast cancer patients as detected by C1q binding. Cancer 1979; 44 (05) 1636-1640
  • 20 Abraham T, Balaram P. Circulating immune complexes in patients with squamous cell carcinoma of the oral cavity. Indian J Cancer 1987; 24 (03) 133-140
  • 21 Ristow SS, Rossen RD, Fryd DS, McKhann CF. Circulating immune complexes in colon cancer patient sera. Cancer 1979; 43 (04) 1320-1327